• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

0.3420 +0.0005 (+0.15%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,014,603
Open 0.3505
Bid (Size) 0.3350 (300)
Ask (Size) 0.3510 (2,100)
Prev. Close 0.3415
Today's Range 0.3250 - 0.4025
52wk Range 0.3345 - 47.50
Shares Outstanding 15,859,280
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
Today 8:36 EDT
New Preclinical Findings Identify Potential Strategy to Remodel Resistant Tumor State & Restore Therapeutic Vulnerability 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
October 14, 2026
Scientific Reports Paper Shows Synergistic Trypsinogen/Chymotrypsinogen A Combination (1:6) Inhibits Angiogenesis, Migration, Invasion and EMT While Delivering Significant Tumor Reduction in Orthotopic... 
From Propanc Biopharma, Inc.
Via GlobeNewswire

Performance

52-Week Range 99.3% below 52-week high
0.3420
0.3352W Low 47.5052W High
1 Week 31.0% below 1-week high
0.331W Low 0.501W High

Propanc Biopharma, Inc. - Common Stock (PPCB) traded between $0.33 and $47.50 over the past 52 weeks and last traded at $0.34, 99.3% below its 52-week high. Over the past week it ranged between $0.33 and $0.50.

Past 12 Months
-29.6%
-58.3%
-78.5%
-87.1%
-97.6%
-99.2%
1W -$0.14
1M -$0.48
3M -$1.25
6M -$2.32
YTD -$13.95
1Y -$42.91

PPCB was -99.2% over the past year, -87.1% over six months, -97.6% year to date, -29.6% in the last week.

12 Months vs Market
PPCB
-99.2%
DIA
+12.2%
SPY
+14.7%
QQQ
+17.9%
IWM
+8.0%

Over the past 12 months PPCB returned -99.2% versus DIA (Dow) +12.2%, SPY (S&P 500) +14.7%, QQQ (Nasdaq 100) +17.9% and IWM (Russell 2000) +8.0%.

Volume & Liquidity 1.13× 3-mo avg
Today 2,014,603 3-mo avg 1.8M
1W
345.8K
1M
310.5K
3M
1.8M
6M
2.8M
YTD
1.9M
1Y
1.5M

PPCB most recently traded 2,014,603 shares against a 3-month average daily volume of 1.8M.

More News

Read More
News headline image
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
October 07, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
September 29, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
September 22, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
September 16, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
September 09, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
Friday's session: top gainers and losers ↗
August 28, 2026
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-08-27: top gainers and losers in today's session. ↗
August 27, 2026
Via Chartmill
These stocks are the most active in today's session ↗
August 27, 2026
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
August 27, 2026
Via Benzinga
These stocks are moving in today's session ↗
August 27, 2026
Via Chartmill
News headline image
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
August 27, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
August 18, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
August 12, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
August 06, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
August 05, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
July 21, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
July 07, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
Thursday's session: gap up and gap down stocks ↗
July 02, 2026
Via Chartmill
News headline image
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
July 02, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
June 16, 2026
From Propanc Biopharma, Inc.
Via GlobeNewswire
These stocks that are showing activity before the opening bell on Friday. ↗
June 12, 2026
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-06-11: top gainers and losers in today's session. ↗
June 11, 2026
Via Chartmill
These stocks are the most active in today's session ↗
June 11, 2026
Via Chartmill

Frequently Asked Questions

Is Propanc Biopharma, Inc. - Common Stock publicly traded?
Yes, Propanc Biopharma, Inc. - Common Stock is publicly traded.
What exchange does Propanc Biopharma, Inc. - Common Stock trade on?
Propanc Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Propanc Biopharma, Inc. - Common Stock?
The ticker symbol for Propanc Biopharma, Inc. - Common Stock is PPCB on the Nasdaq Stock Market
What is the current price of Propanc Biopharma, Inc. - Common Stock?
The current price of Propanc Biopharma, Inc. - Common Stock is 0.3420
When was Propanc Biopharma, Inc. - Common Stock last traded?
The last trade of Propanc Biopharma, Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Propanc Biopharma, Inc. - Common Stock?
The market capitalization of Propanc Biopharma, Inc. - Common Stock is 5.42M
How many shares of Propanc Biopharma, Inc. - Common Stock are outstanding?
Propanc Biopharma, Inc. - Common Stock has 5M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap